Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, use of the bisphosphonate drug zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years, according to a study appearing in JAMA.
Bone involvement in metastatic cancer is a common clinical problem. Zoledronic acid administered intravenously every 3 to 4 weeks reduces pain and the incidence of skeletal-related events, including clinical fracture, spinal cord compression, radiation to bone, and surgery to bone by 25 to 40 percent.
